Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Completed · Phase 3 · NCT04991935
Conditions: Eosinophilic Esophagitis
At a glance
- Research payments reported, 2025
- $21,321
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 367
About the trial
- Sponsor
- Celgene
- Tested
- CC-93538 (drug)
- Dates
- Started 2022-08-09; completion 2025-08-14
- Results posted
- Yes
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
From ClinicalTrials.gov, last updated 2026-04-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $21,321 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $21,321
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.